Atomo Diagnostics Ltd (ASX: AT1) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Atomo Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$12.63 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
902.43 million
Earnings per share
-0.004
Dividend per share
N/A
Year To Date Return
-61.11%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Atomo Diagnostics Ltd (ASX: AT1)
Latest News
Healthcare Shares
Atomo Diagnostics share price charges higher on expanded COVID-19 testing partnership
AT1 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Atomo Diagnostics Ltd
Atomo Diagnostics Ltd. engages in manufacturing, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. It offers its products through the AtomoRapid range of RDT platforms. The company was founded by John Kelly in 2010 and is headquartered in Leichhardt, Australia.
AT1 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 30 Oct 2026 | $0.01 | $0.00 | 0.00% | 7,899,350 | $0.02 | $0.02 | $0.01 |
| 29 Oct 2026 | $0.02 | $0.00 | 0.00% | 4,569,811 | $0.02 | $0.02 | $0.02 |
| 28 Oct 2026 | $0.02 | $0.00 | 0.00% | 547,368 | $0.02 | $0.02 | $0.02 |
| 27 Oct 2026 | $0.02 | $0.00 | 0.00% | 1,716,160 | $0.02 | $0.02 | $0.02 |
| 26 Oct 2026 | $0.02 | $0.00 | 0.00% | 1,250 | $0.02 | $0.02 | $0.02 |
| 23 Oct 2026 | $0.02 | $0.00 | 0.00% | 10,000 | $0.02 | $0.02 | $0.02 |
| 22 Oct 2026 | $0.02 | $0.00 | 0.00% | 82,000 | $0.02 | $0.02 | $0.02 |
| 21 Oct 2026 | $0.02 | $0.00 | 0.00% | 500,000 | $0.02 | $0.02 | $0.02 |
| 19 Oct 2026 | $0.02 | $0.00 | 0.00% | 20,962 | $0.02 | $0.02 | $0.02 |
| 16 Oct 2026 | $0.02 | $0.00 | 0.00% | 318,285 | $0.02 | $0.02 | $0.02 |
| 15 Oct 2026 | $0.02 | $0.00 | 0.00% | 258,479 | $0.02 | $0.02 | $0.02 |
| 14 Oct 2026 | $0.02 | $0.00 | 0.00% | 14,336 | $0.02 | $0.02 | $0.02 |
| 09 Oct 2026 | $0.02 | $0.00 | 0.00% | 421,141 | $0.02 | $0.02 | $0.02 |
| 08 Oct 2026 | $0.02 | $0.00 | 0.00% | 1,556,120 | $0.02 | $0.02 | $0.02 |
| 07 Oct 2026 | $0.02 | $0.00 | 0.00% | 59,143 | $0.02 | $0.02 | $0.02 |
| 06 Oct 2026 | $0.02 | $0.00 | 0.00% | 1,930,795 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 Dec 2025 | Cheri Walker | Issued | 1,000,000 | $40,000 |
Issue of options.
|
| 12 Dec 2025 | Anthony May | Issued | 700,000 | $28,000 |
Issue of options.
|
| 12 Dec 2025 | Patrick Cook | Issued | 1,400,000 | $56,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Cheri Louise Walker | Executive DirectorInterim CEO | Aug 2026 |
Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. She is currently the Chief Executive Officer of Zeta Corporation. She has previously held senior executive positions at Abcam, Charles River Labs, Qiagen, and Life Technologies, now part of ThermoFisher. She is a member of the Risk Committee.
|
| Mr Anthony May | Non-Executive Director | May 2025 |
Mr May has held various Director roles across international corporations including Hoechst Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With experience across public and private pathology laboratories, as well as sales and management roles in the IVD supply sector. He is the chairperson of the Risk Committee.
|
| Mr Patrick Cook | Non-Executive Director | May 2025 |
Mr Cook has over 35 years of experience as a senior executive in medical devices & point-of-care diagnostics sectors within various multinational, private and listed biotechnology companies. He is member of Risk Committee.
|
| Mr Mathew Leslie Watkins | Company Secretary | Jun 2024 |
-
|
| Mathew Leslie Watkins | Company Secretary |
-
|
|
| Chandra Sukumar | COO |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| GZ Family Holdings Pty Ltd | 89,895,644 | 9.96% |
| Dalraida Holdings Pty Limited | 65,120,000 | 7.22% |
| Global Health Investment Fund | 48,230,000 | 5.34% |
| Wellgrow Investments Pty Ltd | 28,648,649 | 3.17% |
| GZ Super Investments Pty Ltd | 27,027,027 | 2.99% |
| Australia West Holdings Pty | 21,050,000 | 2.33% |
| Mr Xiaoyi Lin | 20,000,000 | 2.22% |
| BNP Paribas Nominees Pty Ltd | 19,455,118 | 2.16% |
| Australia North Holdings Pty | 16,000,000 | 1.77% |
| Citicorp Nominees Pty Limited | 15,985,025 | 1.77% |
| Grand Challenges Canada | 11,390,824 | 1.26% |
| Liverbird Pty Ltd | 10,931,653 | 1.21% |
| I D E Pty Ltd | 9,032,248 | 1.00% |
| John Michael Kelly | 8,991,870 | 1.00% |
| Rue Des Rocs Pty Ltd | 8,000,000 | 0.89% |
| Mark Andrew Smith | 7,790,224 | 0.86% |
| Mr Ian Fredrick Johnson | 7,506,080 | 0.83% |
| Mr Leo James Lynch and Ms Judith Anne Beswick | 7,321,121 | 0.81% |
| Ms Zeyu Shi | 6,934,108 | 0.77% |
| Mr Yichao Yu | 6,558,559 | 0.73% |
